论文部分内容阅读
目的对比分析两种强化降脂方案在老年极高危型脑梗死中的临床疗效。方法 100例老年极高危型脑梗死患者,随机分为对照组和治疗组,各50例。对照组老年患者采取20 mg/晚的阿托伐他汀治疗,并以2.1 mmol/L为低密度脂蛋白达标值的强化降脂方案治疗,治疗组老年患者采取40 mg/晚的阿托伐他汀治疗,并以1.8 mmol/L低密度脂蛋白达标准的强化降脂方案治疗,对比分析两组患者治疗前后脂蛋白、门冬氨酸氨基转移酶、丙氨酸转氨酶以及血糖等水平。结果治疗组老年极高危型脑梗死治疗组之后降脂幅度明显大于对照组(P<0.05);老年极高危型脑梗死患者治疗前后的脂蛋白、门冬氨酸氨基转移酶、丙氨酸转氨酶以及血糖等水平差异均无统计学意义(P>0.05)。两组患者治疗前后临床表现差异均无统计学意义(P>0.05)。结论老年极高危型脑梗死患者采取40 mg/晚的阿托伐他汀治疗以1.8 mmol/L低密度脂蛋白达标准的强化降脂方案治疗,临床疗效优于采取20 mg/晚的阿托伐他汀治疗2.1 mmol/L为脂蛋白达标值的强化降脂方案临床疗效,同时两种强化降脂方案均有着一定的安全性,值得临床推广。
Objective To compare and analyze the clinical effects of two intensive lipid-lowering regimens in elderly patients with very high risk cerebral infarction. Methods 100 cases of elderly patients with very high risk of cerebral infarction were randomly divided into control group and treatment group, 50 cases each. Elderly patients in the control group were treated with 20 mg / night of atorvastatin and 2.1 mmol / L of low-density lipoprotein (LDL) as the standard lipid-lowering regimen. The elderly patients in the treatment group received atorvastatin 40 mg / Treated with low-density lipoprotein (1.8 mmol / L). The levels of lipoprotein, aspartate aminotransferase, alanine aminotransferase and blood glucose were compared between the two groups before and after treatment. Results Compared with the control group, the lipid-lowering rate of the elderly patients with very high-risk cerebral infarction was significantly higher than that of the control group (P <0.05). The levels of lipoprotein, aspartate aminotransferase, alanine aminotransferase As well as the level of blood sugar and other differences were not statistically significant (P> 0.05). There was no significant difference in clinical manifestations between the two groups before and after treatment (P> 0.05). Conclusions Atorvastatin 40 mg / night in elderly patients with very high risk cerebral infarction is superior to lipid lowering regimen with 1.8 mmol / L LDL. The clinical effect is superior to that of atorvastatin 20 mg / night Statin treatment 2.1 mmol / L lipoprotein lipid-lowering regimen for the clinical efficacy of the program, while the two enhanced lipid-lowering regimens have a certain safety, worthy of clinical promotion.